Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

Natura Closes $4.4 million Convertible Debenture Financing

 

 

 

 

 

Natura Naturals Holdings Inc. has successfully closed $4.4 million of convertible debenture financing. The Debentures have a coupon of 8% and a Maturity Date of October 15, 2019 and are convertible into the common shares of Natura Naturals.

 

 

The proceeds will be used for general working capital purposes and to fund the preliminary construction capex of Natura Naturals’ Phase 2 expansion, which will add an additional 463,000 square feet of flowering area to the Leamington facility.

 

 

About Natura Naturals Holdings Inc.

 

 

Based in Leamington, Ontario, Natura Naturals Holdings Inc. is a licensed cultivator of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations. The Company’s cultivation facility is capable of producing plants in a 662,000+ square foot greenhouse facility under optimal growing conditions. Natura Naturals grows high-quality hydroponic cannabis which can be used for various medical and recreational applications. Natura Naturals has an extensive genetics library and continues to develop innovative products for the Canadian and International marketplace.

 

Posted November 6, 2018

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


NexTech Launches AR eCommerce Platform and Signs Deal With ParcelPal for Integration

NexTech AR Solutions (CSE: NTAR) (OTC Pink: NEXCF) (FSE: N29) is ... READ MORE

January 17, 2019

Micron Waste Secures US Biotech Patent

Micron Waste Technologies Inc. (CSE: MWM) (OTC: MICWF) (Frankfurt... READ MORE

January 17, 2019

Altria Group Invests Up to $12M in Lexaria Bioscience's DehydraTECH(TM) Technology

Lexaria Nicotine LLC, (OTCQX: LXRP) (CSE: LXX) a wholly owned sub... READ MORE

January 17, 2019

Cryopreservation company, Acorn Biolabs closes $3.3M seed funding and ramps towards consumer launch

Acorn Biolabs, a biotechnology company focused on delivering an e... READ MORE

January 16, 2019

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

Medunik Canada, a company dedicated to improving the health and q... READ MORE

January 16, 2019

Copyright 2019 The Venture Report